Literature DB >> 26142301

A novel method to predict the proportional risk of sudden cardiac death in heart failure: Derivation of the Seattle Proportional Risk Model.

Ramin Shadman1, Jeanne E Poole2, Todd F Dardas2, Dariush Mozaffarian3, John G F Cleland4, Karl Swedberg5, Aldo P Maggioni6, Inder S Anand7, Peter E Carson8, Alan B Miller9, Wayne C Levy2.   

Abstract

BACKGROUND: Patients with heart failure are at increased risk of both sudden death and pump failure death. Strategies to better identify those who have greatest net benefit from implantable cardioverter-defibrillator (ICD) implantation could reduce morbidity and maximize cost-effectiveness of ICDs.
OBJECTIVE: We aimed to identify baseline variables in patients with cardiomyopathy that are independently associated with a disproportionate fraction of mortality risk attributable to sudden death vs nonsudden death.
METHODS: We used data from 9885 patients with heart failure without ICDs, of whom 2552 died during an average follow-up of 2.3 years. Using commonly available baseline clinical and demographic variables, we developed a multivariate regression model to identify variables associated with a disproportionate risk of sudden death.
RESULTS: We confirmed that lower ejection fraction and better functional class were associated with a greater proportion of mortality due to sudden death. Younger age, male sex, and higher body mass index were independently associated with a greater proportional risk of sudden death, while diabetes mellitus, hyper/hypotension, higher creatinine level, and hyponatremia were associated with a disproportionately lower risk of sudden death. The use of several heart failure medications, left ventricular end-diastolic dimension, or NT-pro brain natriuretic peptide concentrations were not associated with a disproportionate risk of sudden death.
CONCLUSION: Several easily obtained baseline demographic and clinical variables, beyond ejection fraction and New York Heart Association functional class, are independently associated with a disproportionately increased risk of sudden death. Further investigation is needed to assess whether this novel predictive method can be used to target the use of lifesaving therapies to populations who will derive greatest mortality benefit .
Copyright © 2015 Heart Rhythm Society. All rights reserved.

Entities:  

Keywords:  Heart failure; ICD; ICD benefit; Nonsudden death; Proportional risk; Regression analysis; Seattle Proportional Risk Model (SPRM); Sudden death

Mesh:

Year:  2015        PMID: 26142301     DOI: 10.1016/j.hrthm.2015.06.039

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  28 in total

Review 1.  Epidemiology of heart failure with preserved ejection fraction.

Authors:  Shannon M Dunlay; Véronique L Roger; Margaret M Redfield
Journal:  Nat Rev Cardiol       Date:  2017-05-11       Impact factor: 32.419

Review 2.  Baroreflex Activation Therapy in Heart Failure With Reduced Ejection Fraction: Available Data and Future Perspective.

Authors:  Marcel Halbach; Thorsten Fritz; Navid Madershahian; Roman Pfister; Hannes Reuter
Journal:  Curr Heart Fail Rep       Date:  2016-04

3.  Joint Shock/Death Risk Prediction Model for Patients Considering Implantable Cardioverter-Defibrillators.

Authors:  Harrison T Reeder; Changyu Shen; Alfred E Buxton; Sebastien J Haneuse; Daniel B Kramer
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2019-08-15

4.  Does the Implantable Cardioverter-Defibrillator Benefit Vary With the Estimated Proportional Risk of Sudden Death in Heart Failure Patients?

Authors:  Wayne C Levy; Yanhong Li; Shelby D Reed; Michael R Zile; Ramin Shadman; Todd Dardas; David J Whellan; Kevin A Schulman; Stephen J Ellis; Matthew Neilson; Christopher M O'Connor
Journal:  JACC Clin Electrophysiol       Date:  2017-03

5.  Association of Implantable Cardioverter Defibrillators With Survival in Patients With and Without Improved Ejection Fraction: Secondary Analysis of the Sudden Cardiac Death in Heart Failure Trial.

Authors:  Selcuk Adabag; Kristen K Patton; Alfred E Buxton; Thomas S Rector; Kristine E Ensrud; Kairav Vakil; Wayne C Levy; Jeanne E Poole
Journal:  JAMA Cardiol       Date:  2017-07-01       Impact factor: 14.676

Review 6.  New York Heart Association class and the survival benefit from primary prevention implantable cardioverter defibrillators: A pooled analysis of 4 randomized controlled trials.

Authors:  Daniel J Friedman; Sana M Al-Khatib; Emily P Zeitler; JooYoon Han; Gust H Bardy; Jeanne E Poole; J Thomas Bigger; Alfred E Buxton; Arthur J Moss; Kerry L Lee; Richard Steinman; Paul Dorian; Riccardo Cappato; Alan H Kadish; Peter J Kudenchuk; Daniel B Mark; Lurdes Y T Inoue; Gillian D Sanders
Journal:  Am Heart J       Date:  2017-06-09       Impact factor: 4.749

Review 7.  [Baroreflex activation therapy. A novel interventional approach to treat heart failure with reduced ejection fraction].

Authors:  M Halbach; T Fritz; N Madershahian; R Pfister; H Reuter
Journal:  Herz       Date:  2015-11       Impact factor: 1.443

Review 8.  Personalizing Risk Stratification for Sudden Death in Dilated Cardiomyopathy: The Past, Present, and Future.

Authors:  Brian P Halliday; John G F Cleland; Jeffrey J Goldberger; Sanjay K Prasad
Journal:  Circulation       Date:  2017-07-11       Impact factor: 29.690

Review 9.  Left ventricular hypertrophy and sudden cardiac death.

Authors:  Grigorios Giamouzis; Apostolos Dimos; Andrew Xanthopoulos; John Skoularigis; Filippos Triposkiadis
Journal:  Heart Fail Rev       Date:  2021-06-28       Impact factor: 4.214

10.  AnaLysIs of Both sex and device specific factoRs on outcomes in pAtients with non-ischemic cardiomyopathy (BIO-LIBRA): Design and clinical protocol.

Authors:  Valentina Kutyifa; Mary W Brown; Christopher A Beck; Scott McNitt; Crystal Miller; Karlene Cox; Wojciech Zareba; Spencer Z Rosero; Marye J Gleva; Jeanne E Poole
Journal:  Heart Rhythm O2       Date:  2020-11-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.